Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(25 sites)
Finland
Helsinki University Hospital, Helsinki France
CHD Vendée, La Roche-sur-Yon CHRU de Lille - Hopital Claude Huriez, Lille CHU Saint Eloi Département d'Hématologie Clinique, Montpellier CHU Hôtel-Dieu, 1, place Alexis Ricordeau, 44093 NANTES Cedex 1, FRANCE, Nantes CHU NICE - Hôpital Archet, Nice CHU Poitiers - Pôle régional de Cancérologie, Poitiers CHRU Hôpital Bretonneau, Tours Greece
Alexandra General Hospital -Department of Clinical Therapeutics N.K. Univ. of Athens, Athens Italy
AOU Consorziale Policlinico di Bari, Bari A.O. Papa Giovanni XXIII, Bergamo A.O.U. Policlinico S. Martino - Ematologia, Genova Meldola-Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola Ospedale Papardo, Messina A.O.U. Maggiore della Carità Novara, Novara A.O.U. di Parma - U.O Ematologia e CTMO, Parma Fondazione IRCCS Policlinico S. Matteo, Pavia Ospedale Santo Spirito Ospedale -Azienda Sanitaria Locale Di Pescara, Roma Clinica Ematologica Azienda Sanitaria Universitaria Friuli Centrale, Udine Netherlands
Maastricht UMC, Maastricht St. Antonius Ziekenhuis, Nieuwegein Norway
Oslo Myeloma Center, Oslo Last updated October 2024